Du forlater nå GSKs nettsider

Denne lenken tar deg til en nettside som ikke tilhører GSK. GSK er ikke ansvarlig for, går ikke god for og aksepterer intet ansvar for informasjon eller meninger på nettsteder til tredjeparter

Fortsett

Tilbake

SPOTLIGHT Webinar 2025: Jemperli + chemo in advanced/recurrent pMMR endometrial cancer patients
 

Should dostarlimab + chemotherapy be a new standard of care in all eligible first-line endometrial cancer patients?

Prof. Domenica Lorusso

Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/Health/Norway/no-jemperli-chemo-pm-no-dst-vid-250013.mp4

 

 

Management of immune-related side effects in a pMMR endometrial cancer patient

Dr. Adelheid Seebacher

Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/Health/Norway/no-jemperli-management-pm-no-dst-vid-250009.mp4

  

Har du spørsmål om JEMPERLI for dine pasienter? Kontakt oss 

Jemperli trademark is a registered trademark of the GSK group of companies.
© 2025 GSK group of companies or its licensor.